Moreover, the involvement of EGFR in the motility of glioma cells was independently validated by our analyses with two clinically relevant EGFR inhibitors, lapatinib/Tykerb and gefitinib/Iressa (Fig. 5D). This evidence concerns the gene EGFR and central nervous system cancer.